



Cite this: *Analyst*, 2022, **147**, 3692

## *In vitro* toxicity screening of amorphous silica nanoparticles using mitochondrial fraction exposure followed by MS-based proteomic analysis†

Premkumari Kumarathasan,<sup>a</sup> Nazila Nazemof,<sup>\*a,b</sup> Dalibor Breznan,<sup>a</sup> Erica Blais,<sup>a</sup> Hiroyuki Aoki,<sup>c</sup> James Gomes,<sup>b</sup> Renaud Vincent,<sup>a</sup> Sadhna Phanse<sup>c</sup> and Mohan Babu<sup>c</sup>

Silica nanoparticles (SiNPs) are used in consumer products, engineering and medical technologies. Attractive properties of SiNPs (e.g. size/surface-modification) enhance usage and thus the likelihood of environmental/human exposures. The assessment of health risks associated with exposures to SiNPs requires information on their relative potencies and toxicity mechanisms. In this work, phagocytic J774 cells were exposed to amorphous pristine (15, 30, 75 nm) and surface-modified (–NH<sub>2</sub>, –C3COOH, –C11COOH, –PEG) SiNP variants, and internalization was assessed by transmission electron microscopy (TEM), while cellular ATP was measured as a cytotoxicity endpoint. Furthermore, mitochondrial fractions from J774 cells were exposed to these SiNP variants (5, 15 μg mL<sup>-1</sup>), as well as two reference particles (SiNP 12 nm and TiO<sub>2</sub>), and proteomic changes were analyzed by mass spectrometry. Ingenuity Pathway Analysis was used to identify toxicity pathways. TEM analyses showed SiNP internalization and distribution along with some changes in mitochondrial structure. SiNP size- and surface-modification and chemical composition-related changes in mitochondrial proteins, including key proteins of the respiratory complex and oxidative stress, were evident based on high content mass spectrometry data. In addition, the dose-related decrease in cellular ATP levels in SiNP-exposed cells was consistent with related mitochondrial protein profiles. These findings suggest that physicochemical properties can be determinants of SiNP exposure-related mitochondrial effects, and mitochondrial exposures combined with proteomic analysis can be valuable as a new approach methodology in the toxicity screening of SiNPs for risk assessment, with added insight into related toxicity mechanisms.

Received 1st April 2022,

Accepted 12th June 2022

DOI: 10.1039/d2an00569g

[rsc.li/analyst](http://rsc.li/analyst)

## Introduction

Amorphous silica nanoparticles (SiNPs) are engineered nanomaterials (ENM) used in a wide range of applications, and consequently are produced on a large scale. The unique physical and chemical properties of amorphous SiNPs such as their hydrophilicity, biocompatibility and stability make them suitable candidates for a diverse array of consumer products including electronics, paints, cosmetics, food, toothpaste and medical

applications including gene therapy, imaging, and photodynamic therapy, or as excipients in dietary supplements.<sup>1–3</sup> According to the Consumer Products Inventory (CPI) list, almost a fifth of nano-based products claim to contain SiNPs.<sup>3</sup> The release of silica nanoparticles into the environment has been reported.<sup>4</sup> Increased production, use, and environmental release of SiNPs raise concerns of potential exposure and related environmental/human health risks.

Toxicity testing is important to assess the health risk associated with exposure to engineered nanomaterials. Nevertheless, toxicological studies fall short, as opposed to studies on the production and application of these materials. In general, nanoparticle (NP) exposures can occur by various routes such as inhalation, oral ingestion or dermal absorption. Besides, there are various reports on nanoparticle exposures and adverse effects at the cellular level as well as on the innate immune system.<sup>5–7</sup> Exposure to SiNPs *in vitro* or *in vivo*, and corresponding cellular cytotoxicity as well as organ-level (e.g.

<sup>a</sup>Environmental Health Science and Research Bureau, HECSB, Health Canada, Ottawa, ON, Canada. E-mail: [premkumari.kumarathasan@hc-sc.gc.ca](mailto:premkumari.kumarathasan@hc-sc.gc.ca); Fax: +613-946-2600; Tel: +613-957-0209

<sup>b</sup>Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada

<sup>c</sup>Department of Biochemistry, University of Regina, Regina, SK, Canada

†Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2an00569g>



respiratory, cardiovascular, immune and reproductive system) toxicity and mitochondrial dysfunction, are known.<sup>8–15</sup>

Moreover, there are reports on NP exposures and oxidative damage due to reactive oxygen species (ROS) formation, and ROS formation has been suggested as one of the mechanisms by which SiNPs could exert toxicity.<sup>16–21</sup> Environmental pollutant exposures can lead to cellular oxidative stress, which in turn can adversely affect mitochondrial function. Cell metabolism and energy production is critical for cell health, and thus examining mitochondrial integrity after NP exposures can be useful in nanomaterial toxicity testing.

Of the various ENMs currently in commerce, nanosilica is used/produced more, and yet existing knowledge gaps in toxicity information on these materials require more work to generate these data. Although many reports on the toxicity of nanosilica are on mesoporous SiNPs, toxicity data for amorphous SiNPs are limited. Amorphous silica nanomaterials are among the ENMs in commerce in Canada and in the Domestic Substances List (DSL) that require toxicity information for assessment of the health risk associated with these materials. Furthermore, toxicity studies reported thus far on amorphous SiNPs are on different sizes of NPs, but not on nanoforms of amorphous SiNPs. In addition, amorphous SiNP exposure-related toxicity mechanisms are less clear. Moreover, there are relatively many reports on the application of high-content approaches such as genomic/transcriptomic analysis in chemical exposure-related toxicity testing for risk assessment, including nanotoxicology.<sup>22</sup> However, the use of proteomic analysis in the same context that can provide phenotypic information is in its early stages. High-content molecular-level analyses in addition to relative cytotoxic potency estimation can provide mechanistic insight into the toxicity of environmental chemicals, and is of emerging interest in NP toxicity testing.

The objective of this work was to develop an *in vitro* toxicity screening approach based on high-content mass spectrometry-based proteomic analysis of mitochondrial fractions to test for the relative toxicities of amorphous SiNP nanoforms. As a part of this effort, TEM analysis examined the internalization of SiNP nanoforms by J774 cells. In addition, cellular ATP levels in J774 cells exposed to these SiNP nanoforms were measured to assess the cytotoxicity. Also, mitochondrial fractions derived from J774 cells were exposed to different SiNP nanoforms and protein-level changes were analysed using mass spectrometry. Pathway analysis based on proteomic changes provided information on toxicity mechanisms. Moreover, the relationships between the relative potencies of SiNP nanoforms and their physicochemical properties were tested to identify potency determinants.

## Materials and methods

### Materials

Dulbecco's modified Eagle's medium (phenol red-free) and with phenol red, fetal bovine serum (FBS), phosphate buffered

saline (10×), Mitochondria Isolation Kit for Cultured Cells, Halt™ Protease Inhibitor Cocktail, EDTA-Free (100×), Trypan Blue Solution 0.4%, and molecular-weight cut-off filters were purchased from Thermo Scientific (Nepean, ON, Canada). Karnovsky fixative reagent grade and Sorensen's phosphate buffer were from Electron Microscopy Sciences (Hatfield, PA, USA). Ammonium acetate (NH<sub>4</sub>OAc), calcium chloride, trifluoroacetic acid, HPLC grade (TFA), formic acid (FA), acetonitrile (ACN) and ultrapure water were from Sigma-Aldrich (Oakville, ON, Canada). Trypsin/Lys C Mix, mass spec grade and ProteaseMAX™ were from Promega (Madison, WI, USA). α-Cyano-4-hydroxycinnamic acid was purchased from Bruker Daltonics (Bremen, Germany). **Nanoparticles:** Custom-synthesized pristine amorphous silica nanoparticles (SiNPs) of different sizes (15, 30, 75 nm) and the 15 nm surface-modified (–C3–COOH, –C11–COOH, –NH<sub>2</sub>, and –PEG) SiNPs were obtained from Advanced Quantum Materials Inc (AQM, Edmonton, AB, Canada). Here, pristine amorphous non-porous SiNPs were synthesized by a modified Stöber method as reported previously,<sup>23</sup> with a calcination process as a step. Reference particles (SRM-154b titanium dioxide, TiO<sub>2</sub>) included in this study were from the National Institute of Standards and Technology (Gaithersburg, MD, USA). Nano-sized silica (12 nm) served as an additional reference particle (cat. # 718483; Sigma Aldrich, Oakville, ON, Canada).

### Characterization of physicochemical properties of SiNP nanoforms

The size, surface area, functional groups, metal content, polydispersity/aggregation and zeta potential of the SiNP nanoforms in the dry state were analysed as previously described.<sup>23</sup> Briefly, transmission electron microscopy (TEM) images for size distribution of the SiNPs were performed by a JEOL 2010 TEM (with LaB6 electron gun). Brunauer–Emmett–Teller (BET) surface area analysis was done by nitrogen absorption using the ASAP 2020 instrument (Micromeritics, Norcross, GA, USA). Fourier transform infrared (FT-IR) spectroscopic analyses and thermogravimetric analysis (TGA) were performed for functional group analysis using a Thermo Nicolet Magna 750 IR spectrometer and a Mettler Toledo Star TGA/DSC system, respectively. Quantitative nuclear magnetic resonance (NMR) spectroscopy was done in solution state using a Bruker Avance 400 MHz spectrometer to determine the surface functional groups. The metal contents of pristine SiNP samples were analyzed using inductively coupled plasma-mass spectrometry/atomic emission spectroscopy (ICP-MS/AES, Varian Vista-PRO, Mulgrave, Australia). Dynamic light scattering (DLS) and zeta potential measurements were done using the Zetasizer Nano ZS (Malvern Instruments, UK).

### TEM analyses of J774 cells exposed to SiNPs

**Particle preparation for dosing cells.** Amorphous SiNPs variants and reference particles (SiO<sub>2</sub> (12 nm) and SRM-154b TiO<sub>2</sub>) were re-suspended in 1 mL of ultrapure water to make 3 mg mL<sup>–1</sup> of the stock suspension and were diluted appropri-



ately with DMEM (phenol red-free) to obtain the particle suspension for dosing J774 cells.

**Cell culture.** J774 (ATCC® TIB-67™, Cedarlane, USA) mouse monocyte/macrophage cells were maintained following the ATCC protocol. Briefly, the cells were cultured in T-75 flasks in DMEM containing 10% FBS at 37 °C in a 5% CO<sub>2</sub> incubator. At 80% confluency, the cells were harvested. The cells between passages 10 and 20 were used for this work. For TEM, the cells were seeded into 6-well plates at a density of 10 000 cells per mL and were allowed to attach to the surface for 24 h prior to SiNP exposure.

**TEM analyses.** The morphology of J774 cells exposed to SiNPs (30 μg cm<sup>-2</sup>) was visualized by TEM to assess the intracellular localization of the SiNPs. Briefly, after 24 h exposure to SiNP suspensions, the cells were washed in 1× PBS and fixed in Karnovsky's fixative (2% paraformaldehyde + 2.5% glutaraldehyde in 0.1 M phosphate buffer – pH 7.4) for 2 h and then washed in 0.1 M Sorensen's phosphate buffer and stored in the same buffer (400 μL) at 4 °C. Cells were centrifuged at 500g for 2 min, washed with 0.1 M phosphate buffer – pH 7.4 at RT, and then treated with osmium tetroxide 1% + 1.5% potassium ferrocyanide (aq) for one hour at 40 °C, washed with 0.1 M phosphate buffer – pH 7.4, and dehydrated in a series of increasing concentrations of ethyl alcohols (30–100%) and finally with propylene oxide. Cells were then treated sequentially with mixtures of Epon and propylene oxide (1 : 1, 2 : 1, 3 : 1) and then with Epon, and finally the cell pellet was treated with Epon and cured at 60 °C for 48 h alone for embedding the cells in this resin. Embedded cells were then sectioned using a microtome. Ultra-thin sections (*ca.* 70 nm thickness) collected on 200 mesh copper grids with a carbon support film (3 grids per sample) were stained with 4% uranyl acetate and Reynolds lead citrate, and the samples (duplicates) were examined using an FEI Tecnai 12 TEM (Advanced Microscopy Techniques, NJ, USA) at an accelerating voltage of 120 kV and equipped with a Gatan Ultrascan 4000 4k × 4k CCD Camera System Model 895.

### J774 cell exposure to SiNPs and cytotoxicity analysis (cellular ATP levels)

Murine monocyte/macrophage (J774) cells (ATCC; VA, USA) were maintained as described previously.<sup>24</sup> Cells were initially cultured in 75 cm<sup>2</sup> tissue culture flasks (Corning, NY, USA) at 37 °C with 5% CO<sub>2</sub> and 95% relative humidity. For the exposure experiments, cells were cultured in DMEM (phenol red-free) with 10% FBS, in 96-well plates at 20 000 cells per well (~0.32 cm<sup>2</sup> surface area; 100 μL medium), for 24 h prior to particle exposure. Cell counts were determined using the Multisizer 3 Coulter Counter (Beckman Coulter, ON, Canada). The stock particle suspensions (RT) were sonicated for 20 min, and working suspensions were prepared in serum-free medium (100 μL) and re-sonicated for 10 min, before dosing cells at 0, 10, 30 and 100 μg cm<sup>-2</sup> (well surface area, 96-well plate), where cells were in 100 μL of DMEM + 10% FBS. After dosing, the final concentration of FBS in cell culture medium (200 μL) was 5%. Cells were incubated after nanoparticle

exposure at 37 °C with 5% CO<sub>2</sub> and 95% relative humidity for 24 h. Cellular ATP levels (energy metabolism) were determined as a cytotoxicity endpoint using a luminescence-based ViaLight Plus assay on the BioTek Synergy 2 multimode plate reader, following the manufacturer's recommended protocol. Exposure experiments were conducted three times (*n* = 3), with triplicate samples per experiment.

### Exposure of J774 cell mitochondrial fractions to SiNPs for mass spectrometry-based proteomic analysis

**Particle preparations.** For mitochondrial exposure, all amorphous SiNP nanoforms – pristine (15, 30, 75 nm), 15 nm surface-modified (–C3–COOH, –C11–COOH, –NH<sub>2</sub>, and –PEG), and reference particles (12 nm SiO<sub>2</sub> and SRM-154b TiO<sub>2</sub>) – were re-suspended in 1 mL of mitochondria isolation reagent C from the Mitochondria Isolation Kit (Thermo Scientific, ON, Canada) to make 3 mg mL<sup>-1</sup> of the stock suspension. The suspensions were vortexed for 30 s and sonicated on ice for 20 min in a bath sonicator. Sonicated samples were vortexed for 30 s and agitated by a rocker. The suspended particles were diluted with mitochondria isolation reagent C to obtain the concentration of 5 and 15 μg mL<sup>-1</sup>.

**Isolation of mitochondria from J774 cells.** Mitochondria were isolated from J774 mouse macrophage cells using the Mitochondria Isolation Kit (Thermo Scientific, ON, Canada; Catalog no. 89874) specifically for cell cultures following the protocol provided by the supplier. Briefly, a 1 mL aliquot of J774 cell suspension in DMEM with 10% FBS (containing 20 000 000 cells) was centrifuged at 850g for 2 min. (Note: Multiple tubes containing 20 000 000 cells per tube were processed using this process simultaneously.) Then, 800 μL of Mitochondria Isolation Reagent A was added to the pellet, and incubated on ice. After 2 min, 10 μL of Mitochondria Isolation Reagent B was added to the mixture, incubating it on ice for 5 min, vortexing it every min. After 5 min, 800 μL of Mitochondria Isolation Reagent C was added. The tube was inverted gently several times and centrifuged at 700g for 10 min at 4 °C, and the supernatant was collected. Pooled mitochondrial fractions were subdivided as required for the exposure experiment and centrifuged at 12 000g for 15 min at 4 °C, and the mitochondrial pellets were washed with Mitochondria Isolation Reagent C, and kept on ice for downstream processing.

**Exposure to SiNPs.** The mitochondrial fraction (cell equivalent of 10 000 000 cells) was exposed to SiNPs at concentrations of 5 and 15 μg mL<sup>-1</sup>. Briefly, 200 μL of the particle suspensions was added to the mitochondrial pellet, vortexed and incubated for 2 h at 37 °C. These samples were then vortexed and centrifuged at 12 500g for 10 min. The mitochondrial pellet was washed three times with 25 μL aliquots of Mitochondria Isolation Reagent C, and stored at –80 °C, for proteomics analysis.

**Sample processing for proteomic analysis.** Mitochondrial pellets exposed to SiNPs were re-suspended in 100 μL of cold deionized water containing protease inhibitor cocktail. After centrifugation at 900g for 15 min, the samples were re-frozen



at  $-80\text{ }^{\circ}\text{C}$ . After 10 min incubation, the mitochondrial pellets were thawed on ice, at room temperature (RT). After three freeze/thaw cycles, the mitochondrial fractions were sonicated for 10 min (with ice added to the bath), and centrifuged at  $10\,000g$  for 10 min, and the supernatants were fractionated using molecular weight cut-off filters (MWCO) to obtain fractions:  $<10$ ,  $10$ – $50$ ,  $50$ – $100$  kDa as described previously.<sup>25</sup> Initially  $10$  kDa MWCO filters were pre-wetted using deionized water ( $300\text{ }\mu\text{L}$ ) at  $14\,000g$  for 10 min, filtrates were discarded, and mitochondrial lysates ( $100\text{ }\mu\text{L}$ ) diluted with deionized water ( $200\text{ }\mu\text{L}$ ) were added to these filters, and centrifuged at  $14\,000g$  for 10 min. The filtrates were removed, while the residues were diluted with  $175\text{ }\mu\text{L}$  aliquots of  $10\%$  ACN (aq), inverted into new receiver tubes and spun at  $5000g$  for 3 min for the collection of solubilized residues which were then transferred to a pre-wetted  $50$  kDa MWCO filter set-up and spun at  $14\,000g$  for 15 min. The resulting filtrates were saved and the residues were solubilized as mentioned before, transferred to a pre-wetted  $100$  kDa MWCO filter set-up and spun at  $14\,000g$  ( $15$  min). Filtrates obtained from MWCO fractionation were evaporated to complete dryness under a gentle stream of high-purity  $\text{N}_2$  (g). These evaporated fractions were resuspended in  $25\text{ }\mu\text{L}$  of  $50$  mM  $\text{NH}_4\text{OAc}$  ( $\text{pH}$   $7.4$ ) and were treated with  $2\text{ }\mu\text{L}$  ProteaseMAX and  $10\text{ }\mu\text{L}$  of Trypsin/Lys C enzyme solution ( $50\text{ }\mu\text{g mL}^{-1}$ ) for enzymatic digestion,<sup>26</sup> vortexed gently and then centrifuged at  $5000g$  ( $1$  min). Samples were then sonicated for  $5$  min in an ice bath, centrifuged at  $5000g$  ( $1$  min), and incubated overnight in a water bath, at  $37\text{ }^{\circ}\text{C}$ . Enzymatic digestion reaction was quenched with  $5\text{ }\mu\text{L}$  of  $5\%$  TFA in deionized water, and vortexed ( $3$  s), and samples were centrifuged at  $14\,000g$  ( $10$  min) to remove any residues. Supernatants were stored at  $-80\text{ }^{\circ}\text{C}$  for mass spectrometry analysis by MALDI-TOF-TOF-MS and LC-Orbitrap.

### Mass spectrometry analyses

**Proteomic profiling by MALDI-TOF-TOF-MS.** Aliquots ( $1.5\text{ }\mu\text{L}$ ) of enzymatically digested samples were spotted on the AnchorChip target plate ( $600/384\text{F}$ , Bruker Daltonics Ltd, Bremen, Germany), after which a  $1.5\text{ }\mu\text{L}$  aliquot of freshly prepared  $\alpha$ -cyano-4-hydroxycinnamic acid ( $5\text{ mg mL}^{-1}$ ) matrix was added. These sample-matrix spots were dried at RT and were washed with  $1.5\text{ }\mu\text{L}$  ice-cold  $1\%$  TFA (aq), as reported previously.<sup>27</sup> Multiple spots per sample ( $n = 5$  for MS survey scans) were analyzed using the AutoFlex (III) MALDI-TOF-TOF-MS platform (Bruker Daltonics, Bremen, Germany) in a reflectron positive mode. All settings such as gain, pulsed ion extraction, laser power and number of laser shots were optimized for enhanced peptide signals. Mass calibration was done using a peptide-II calibration standard (Bruker Daltonics, Billerica, MA). Survey MS scans for peptide  $m/z$  profiles were obtained and mass spectral data were analysed using the bioinformatics software ClinPro Tools (Bruker Daltonics Ltd, Bremen, Germany) to assess SiNP exposure-related mitochondrial protein profile changes.<sup>25,26</sup>

### LC-MS/MS analysis and protein identification

Another set of enzymatically digested samples were desalted using ZipTip  $\text{C}_{18}$  pipette tips (Millipore, catalog number ZTC18S096), according to the manufacturer's protocol, were dried by evaporation using a Speed Vac concentrator (Savant) and were stored at  $-20\text{ }^{\circ}\text{C}$  prior to MS analysis. Before MS analysis, the dried peptides were immediately re-suspended in  $1\%$  FA. All samples were analyzed by nano LC coupled to an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Chromatographic separation of peptides was performed on a Proxeon EASY-nLC 1000 System (Thermo Fisher Scientific) equipped with a Thermo Scientific™ Acclaim™ PepMap™  $\text{C}_{18}$  column,  $15\text{ cm} \times 50\text{ }\mu\text{m ID}$ ,  $3\text{ }\mu\text{m}$ ,  $100\text{ }\text{\AA}$  employing a water/ACN/ $0.1\%$  FA gradient. Five  $\mu\text{L}$  aliquots of Tryp/LysC digested and  $\text{C}_{18}$  cleaned-up samples were loaded on an LC column, and the flow rate was set at  $0.3\text{ }\mu\text{L min}^{-1}$ . Peptides were separated initially with  $1\%$  ACN, which was raised to  $3\%$  ACN over  $2$  min, and then was increased to  $24\%$  of ACN over  $170$  min, followed by a linear increase to  $100\%$  of ACN over  $29$  min, followed by a washing period of  $10$  min with  $100\%$  of ACN. The eluted peptides were directly sprayed into the mass spectrometer using positive electrospray ionization (ESI) at an ion source temperature of  $250\text{ }^{\circ}\text{C}$  and an ion spray voltage of  $2.1\text{ kV}$ . Full-scan MS spectra ( $350$ – $2000\text{ }m/z$ ) were acquired in the Orbitrap Elite at  $60\,000$  ( $m/z$   $400$ ) resolution. The automatic gain control settings were  $1\text{E}6$  for full FTMS scans and  $5\text{E}4$  for MS/MS scans. Fragmentation was performed with collision-induced dissociation (CID) in the linear ion trap when the ion intensity was  $>1500$  counts. The most intense ions were isolated for ion trap CID with charge states  $\geq 2$  and sequentially isolated for fragmentation using the normalized collision energy set at  $35\%$ , activation Q at  $0.250$  and an activation time of  $10$  ms. Ions selected for MS/MS were dynamically excluded for  $30$  s. Calibration was performed externally with Pierce LTQ Velos ESI Positive Ion Calibration Solution (Thermo Fisher Scientific, catalog number 88322). The Orbitrap Elite mass spectrometer was operated with Thermo Xcalibur software. All RAW files were converted to mzXML using ReAdW-4.3.1. The mzXML files were analyzed using Thermo Proteome Discoverer (PD) 2.2. Database searches were performed with SEQUEST HT and MS Amanda 2.0 search algorithms with a few modifications: trypsin digestion, 2 maximum missed cleavages, a precursor mass tolerance of  $10$  ppm, a fragment mass tolerance of  $0.6$  Da in the case of SEQUEST HT, and  $5$  ppm MS1 tolerance and  $0.02$  Da MS2 tolerance in the case of MS Amanda 2.0, a fixed modification of  $+57.021$  Da (carbamidomethylation) on cysteine, and variable modifications of  $+15.995$  Da (oxidation) on methionine,  $+79.966$  Da (phosphorylation) on serine, threonine, and tyrosine,  $+33.061$  Da (chlorination) on tryptophan and tyrosine, and  $+44.985$  Da (nitrosylation) on tryptophan and tyrosine. A reverse database search was performed for both search engines to determine the spectral false discovery rate (FDR), and the subsequent results were filtered using an FDR of  $\leq 1\%$ . The FASTA database used was a mouse proteome downloaded from UniProt with the addition of  $635$  common





contaminants such as proteases, keratins and ubiquitins, yielding a total of 17 239 non-redundant protein sequences. Prior to quantitation, the Spectrum Files RC node in PD 2.2 was utilized to perform spectrum recalibration. The false discovery rate (FDR) was determined by using a target-decoy search strategy. Only high-confidence peptides defined by SEQUEST HT or MS Amanda 2.0 with a 1% false discovery rate by Percolator were considered for the peptide identification. The mass spectrometry proteomics data were deposited with the ProteomeXchange Consortium *via* the PRIDE<sup>1</sup> partner repository with the dataset identifier PXD027593.

### Particle potency estimates

The dose–response data for protein changes (*i.e.* protein intensity data) or the cytotoxicity analysis data (*i.e.* cellular ATP levels) for the particle exposure groups were normalized to the corresponding control group value (no particle treatment), to obtain a fold-effect (FE) for each particle dose. Potency estimate ( $\beta$ ) was derived from the following equation:

$$FE = (\text{Dose} + 1)^\beta$$

where  $\beta$  represents the rate of change of the dose with respect to the logarithm of the fold-effect for a given endpoint.<sup>28</sup> The dose–response data were fitted using CurveExpert v1.4 (D. Hyams, TN, USA).

### Statistical and bioinformatic analyses

The associations between the physicochemical characteristics of SiNPs and the potency values ( $\beta$ ) for these SiNP exposure-related mitochondrial protein or cytotoxicity (cellular ATP) responses were tested by Pearson product moment correlation analyses using SigmaPlot v13.0 (Systat Software, San Jose, CA, USA).

Mass spectral intensities of mitochondria-related proteins after SiNP exposures were normalized to control (no particle treatment) values to obtain protein fold-changes. These protein fold-change data were used to conduct the following bioinformatics analyses. A heat map with hierarchical clustering was employed to visualize differential patterns of protein responses as related to the different particle exposures. The

analysis was done using the hierarchical clustering option in GenePattern (<https://genepattern.broadinstitute.org/gp/pages/login.jsf>) and formatted in Java treeview (<https://jtreeview.sourceforge.net/>). Furthermore, Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, <https://www.ingenuity.com>) was used to analyse for protein interactions, biofunctions and canonical pathways using the protein fold-change data. The fold-change cut off was set at 1.5, and  $p < 0.05$  and a z score of 2 were used for the identification of canonical pathways and disease/biological functions.

## Results

### Characterization of physicochemical properties

The TEM images shown in Fig. 1A–C illustrate the sizes and shapes of the SiNPs in the dry state. The particles are spherical in shape with some aggregation observed at the 15 and 30 nm sizes, while 75 nm SiNPs appeared to be dispersed well. Quantitative analysis data for the key physicochemical properties including size and surface area (based on TEM images) as well as BET surface area, DLS hydrodynamic size, surface charge (zeta potential), surface functional group content (by TGA and quantitative NMR analysis) and elemental analysis results for these SiNPs are presented in Table 1. The results of the elemental analysis are provided only for the pristine NPs and not for the surface-modified NPs; since the surface-modified SiNPs were derived from their correspondingly sized pristine counterparts, the latter NPs would only vary in organic surface composition. Elemental analysis revealed that the total metal, reactive and transition metal contents were the highest for the pristine 15 nm SiNPs compared with their 30 and 75 nm counterparts. Also, surface area by TEM was the highest for the 15 nm pristine SiNPs. Surface functional groups were higher for the  $-\text{NH}_2$  group-containing SiNP (Table 1).

### Cellular uptake of SiNPs by TEM analyses

A comparative assessment of the cellular uptake and intracellular localization of these nanoparticles after 24 h exposure of the




Fig. 1 TEM analysis results for dry pristine amorphous silica (A) 15 nm, (B) 30 nm, and (C) 75 nm nanoparticles (SiNPs).



Table 1 Physicochemical properties of the SiNPs

| Physicochemical properties |                    |                        |                         |  |  |                |               |               |                          |               |   |  |
|----------------------------|--------------------|------------------------|-------------------------|--|--|----------------|---------------|---------------|--------------------------|---------------|---|--|
| SiNP ID                    | Total metals (ppm) | Bioactive metals (ppm) | Transition metals (ppm) | BET SA (m <sup>2</sup> g <sup>-1</sup> ) | TEM SA (m <sup>2</sup> g <sup>-1</sup> ) | DLS size (nm)  | TEM size (nm) | DLS/TEM ratio | TEM SA × (DLS/TEM Ratio) | Zeta pot (mV) | TGA functional groups (μmol g <sup>-1</sup> ) | qNMR functional groups (μmol g <sup>-1</sup> ) |
| 15 nm-P                    | 848.24             | 1649.80                | 785.15                  | 29.6                                     | 130.0                                    | 657.4 ± 172.4  | 17.2 ± 3.5    | 38.2          | 4966.0                   | -15.9 ± 1.2   | —   | —  |
| 30 nm-P                    | 615.55             | 1184.60                | 541.30                  | 97.2                                     | 78.8                                     | 1128.0 ± 423.8 | 28.8 ± 3.5    | 39.2          | 3089.0                   | -13.4 ± 2.8   | —   | —  |
| 75 nm-P                    | 476.36             | 918.45                 | 419.10                  | 17.0                                     | 28.8                                     | 260.1 ± 30.2   | 78.2 ± 5.5    | 3.3           | 95.0                     | -16.6 ± 2.3   | —   | —  |
| 15 nm-C3-COOH              | —                  | —                      | —                       | 162.0                                    | —  | 530.6 ± 49.4   | —             | 30.8          | 4004.0                   | -17.8 ± 0.7   | 351   | 522 ± 55                                       |
| 15 nm-C11-COOH             | —                  | —                      | —                       | 20.1                                     | —  | 445.3 ± 82.0   | —             | 25.9          | 3367.0                   | -21.4 ± 4.5   | 325   | 196 ± 13                                       |
| 15 nm-NH <sub>2</sub>      | —                  | —                      | —                       | 9.2                                      | —  | 822.4 ± 177.5  | —             | 60.0          | 9858.0                   | -6.7 ± 1.7    | 1232  | 757 ± 137                                      |
| 15 nm-PEG                  | —                  | —                      | —                       | 19.6                                     | 164.3                                    | 528.3 ± 54.2   | 13.7 ± 1.4    | 38.6          | 6342.0                   | -2.1 ± 0.5    | 180   | 196 ± 5  |

Metal contents of SiNP nanoforms were determined by ICP-MS/AES; DLS size and zeta potential values for SiNPs were in 0.5 M K<sub>3</sub>PO<sub>4</sub> buffer (pH 7.4). DLS/TEM ratio is a measure of agglomeration; TEM SA × (DLS/TEM ratio) provides information on the available reaction surface.

J774 cells to these SiNPs is shown in Fig. 2A–C. Imaging of the control cells that were not exposed to any particle revealed typical interphase J774 monocyte/macrophage morphology with prominent nuclei, granular cytoplasm, membrane protrusions, vacuoles and mitochondria with visible double membranes (Fig. 2A). SiNPs of all sizes were taken up by macrophage cells. In cells exposed to SiNPs of 15 nm size (Fig. 2B), nanoparticles were observed in the cytoplasm, and in some cases particles seemed to be present in aggregates inside larger vesicles or were in endosome-like vesicles in the cytoplasm (data not shown). The pristine 30 nm-sized SiNPs were taken up by the J774 cells as dense agglomerates/aggregates (see the black arrows) present in large cellular vesicles (Fig. 2C). Mitochondrial structural anomalies such as less obvious external membranes, and less obvious or absent cristae, and vacuolated mitochondria were seen with the smaller sized SiNPs (15, 30 nm) (Fig. 2B–C), while autophagosomes with particle aggregates and some vacuolated mitochondria were seen in cells exposed to 75 nm pristine SiNPs (data not shown).


### J774 cellular ATP responses to SiNP exposures

J774 cells exposed to these SiNP variants showed decreased ATP responses with an increased dose of NP exposure. Three-way ANOVA results (data not shown) indicated a size main effect ( $p < 0.027$ ), with smaller size SiNPs being relatively more potent (Table 2). The 15 nm pristine SiNPs are associated with the highest potency value  $\beta$  compared with their pristine 30 and 75 nm counterparts. Also, some surface modifications led to reduced cytotoxic potency values within the 15 nm size particles (-C3-COOH, NH<sub>2</sub>), whereas the others increased (-C11-COOH, PEG). Moreover, cellular ATP levels exhibited a negative trend of association with the BET surface area ( $r = -0.560$ ,  $p = 0.191$ ).

### Mitochondrial protein changes after exposure to SiNPs

Initial mass-spectral profiling by MALDI-TOF-TOF-MS analysis revealed SiNP exposure-specific mass-spectral changes in tryptic peptide profiles as shown by Fig. 3A–F. For instance, decreased tryptic peptide intensities are noticed with exposure to SiNPs irrespective of their size and modifications compared with the control particle untreated mitochondrial digests (e.g.  $m/z$  region 1000–2400 Da). In addition, exposure to 12 nm pristine amorphous SiNP (used as a positive control in this study, from another supplier) exhibited a different mitochondrial tryptic peptide profile compared with the almost similar-sized (15 nm) pristine amorphous SiNPs used in this toxicity screening study. In addition, size-related and surface modification-related changes within the same-sized SiNPs' tryptic peptide signal intensities are observed in these  $m/z$  profiles ( $m/z$  region 1100–2400 Da). Similarly, in-depth LC-Orbitrap analysis results (with overall standard deviation (SD) associated with the normalized analyte (protein) intensities for replicate analysis better than 1%, across all SiNP exposures) exhibited different SiNP size-related and surface modification-related changes in various mitochondria-related proteins ( $n = 213$ ) at the doses tested (0, 5 and 15  $\mu\text{g mL}^{-1}$ ). However, 32 of these mitochondrial proteins were detectable (based on intensity values) across all particle





**Fig. 2** TEM results for J774 cells exposed for 24 h to SiNPs, showing internalization of nanoparticles and related changes in subcellular compartments. Note: (A) Control cells show a clear double-membrane feature of the mitochondria. (B) Granules of nanoparticles are seen in the cytoplasm of J774 cells exposed to 15 nm pristine SiNPs, and the mitochondrial membranes are not clear compared with the controls. (C) Mitochondrial membranes are still less clear after 30 nm SiNP-pristine exposures compared with those of the control cells. After these SiNP exposures, aggregated/agglomerated nanoparticles are encapsulated into secondary lysosomes, and in frame C, after 30 nm pristine SiNP exposure, vacuolated mitochondria are observed (red arrow).

**Table 2** J774 cell cytotoxic potencies after exposure to SiNPs based on cellular ATP levels

| SiNP nanoform              | $\beta$ (relative potencies) |
|----------------------------|------------------------------|
| 15 nm SiNP-P               | 0.027                        |
| 30 nm SiNP-P               | 0.012                        |
| 75 nm SiNP-P               | 0.021                        |
| 15 nm SiNP-C3COOH          | 0.012                        |
| 15 nm SiNP-C11COOH         | 0.024                        |
| 15 nm SiNP-NH <sub>2</sub> | 0.011                        |
| 15 nm SiNP-PEG             | 0.026                        |

exposures while the other proteins were expressed with some SiNP exposures only. Of the proteins detected for all treatments, respiratory chain proteins (*e.g.* NADH:ubiquinone oxidoreductase, succinate dehydrogenase, cytochrome c oxidase, electron transfer flavoprotein subunit), ATP synthase subunit and antioxidant enzymes (*e.g.* superoxide dismutase 2 – MnSOD) were a few of them, and exposure dose-related changes were also seen in these protein responses (ESI Table 1<sup>†</sup>).

#### Association between the physicochemical properties of SiNPs and mitochondrial protein changes

Analyses of heat map and hierarchical clustering results revealed nanoparticle exposure dose-related up- (red) and






Fig. 3 MALDI-TOF-TOF-MS profiles illustrating mitochondrial protein changes after SiNP exposure.

down- (green) regulation of different mitochondrial proteins (Fig. 4). Most proteins were down-regulated at the higher dose ( $15 \mu\text{g mL}^{-1}$ ) of particle treatment. At the low-dose ( $5 \mu\text{g mL}^{-1}$ ) particle exposure, the smaller particle size appeared to exhibit increased protein expression compared with the other particles. Also, the relationships between SiNP potency values ( $\beta$ ) derived from mitochondrial protein dose-response data as mentioned previously and SiNP physicochemical properties are illustrated in Table 3 (only significant correlations are given here). In general, these results indicated negative associations between SiNP size and SiNP potencies ( $\beta$ ) derived based on aspartate amino transferase, acyl carrier protein responses. Similarly, a positive correlation was seen between metal contents (for total, bioactive, transition metal contents) and relative SiNP potencies ( $\beta$ ) based on malate dehydrogenase, glutamate dehydrogenase, aconitate hydratase, ATP synthase subunit delta, NADH:ubiquinone oxidoreductase, NFU 1 iron-sulfur cluster scaffold protein, and cytochrome c oxidase subunit N protein responses. Also, negative correlations were observed between surface modifications and  $\beta$  values for dihydrolipoyl dehydrogenase, aspartate aminotransferase, malate dehydrogenase, and cytochrome c oxidase as shown in Table 3.


### Pathway analyses

Pathway analysis based on protein fold-changes (compared with no particle treatment controls) using IPA (fold-change cut off = 1.5;  $p < 0.05$  and met the criteria of an activation z score of 2) identified the top 5 canonical pathways to be oxidative phosphorylation, the TCA cycle, fatty acid  $\beta$  oxidation, valine degradation I and isoleucine degradation I (Fig. 5A). Similarly, some of the biological functions affected included the quantity of carnitine, concentration of fatty acid, energy expenditure, accumulation of lipid, metabolism of reactive oxygen species, energy homeostasis, cell death, and apoptosis (Fig. 5B), and the top 5 upstream regulators identified were CLPP, INSR, PPARGC1A, MAP4K4 and PTEN (Fig. 5C). Detailed analyses of these different biological events revealed particle-specific increased or decreased protein expressions in the different pathways. For instance, increased or decreased expression or no change in the constituent proteins of the fatty acid oxidation pathway appeared to vary with SiNP form and exposure dose.

Correlation tests for cellular ATP vs. mitochondrial ATP synthases identified positive trends of the associations (pristine SiNPs: cellular ATP vs. ATP synthase alpha subunit,  $r =$







**Fig. 4** Heatmap and hierarchical clustering demonstrating mitochondrial protein effects (normalized to controls, log 2 transformed) related to the different SiNP exposures.

0.807 ( $p = 0.403$ ); cellular ATP vs. ATP synthase beta subunit,  $r = 0.948$  ( $p = 0.206$ ); all SiNPs: cellular ATP vs. ATP synthase alpha subunit,  $r = 0.541$  ( $p = 0.210$ ); cellular ATP vs. ATP synthase beta subunit,  $r = 0.446$  ( $p = 0.315$ )).

## Discussion

There are reports on amorphous SiNP toxicity testing by *in vitro* cellular exposures or *in vivo* exposures using animal models (inhalation/intratracheal instillation, intravenous/intraperitoneal, etc.) with inconsistency in the study findings.<sup>29,30</sup> Furthermore, most of these studies focused on SiNP size-related effects. Not much is known in terms of the toxicity testing of SiNP nanoforms, for instance, on surface-modified SiNPs. Moreover, some of these study findings have implicated SiNP exposures in driving adverse organ/system-level effects including cardiovascular effects.<sup>22,31</sup> Emerging evidence also points towards a link between the mitochondrial toxicity of SiNPs and the observed cardiovascular effects.<sup>8,14</sup> Amorphous SiNP exposure-related toxicity mechanisms need further exploration, especially with respect to potential mitochondrial function-related effects.

In this study, we have therefore focused on understanding SiNP nanoform exposure-related mitochondrial changes. In this context, the initial TEM analysis of J774 cells exposed to SiNPs revealed an internalization of nanoparticles into the cells. For instance, the smaller SiNPs, namely the pristine

15 nm size, are scattered in the cytoplasm, while in the case of the increased-sized SiNP forms, aggregated particles are located in the vacuoles (Fig. 2). In addition, the TEM results show that 15 nm pristine SiNPs are in the proximity of the endoplasmic reticulum (ER) and mitochondrial membrane, suggesting a potential NP interaction with these intracellular organelles (Fig. 2). We also observed that the mitochondrial double-membrane structure was less clear after the SiNP exposure of J774 cells compared with controls. Furthermore, a reduction of cristae in the mitochondria and vacuolated mitochondria (Fig. 2C) are observed in the SiNP-exposed cells (e.g. 30 nm). Similar observations of a loss of cristae and vacuolated mitochondria have been noted in SiNP-exposed HUVEC cells and cardiomyocytes.<sup>8,14</sup> Also, the TEM results for 75 nm SiNP-exposed cells showed vacuolated mitochondria and autophagosomes containing NPs (data not shown).

Mitochondria are subcellular organelles and the energy production units of a cell with a key role in maintaining and regulating the metabolic function of cells. An imbalance in mitochondrial functioning can be detrimental to cell viability. Mitochondrial dysfunction is implicated in various metabolic diseases including cardiovascular disease, diabetes, cancer and neurodegenerative disease.<sup>32–37</sup> Also, cardiac and mitochondrial dysfunction has been linked to increased ROS production after ENM exposure.<sup>38</sup>

There are emerging reports implicating different types of nanomaterial exposure in mitochondrial toxicity in various cells/organs.<sup>39–41</sup> Our previous work on commercially obtained





**Table 3** Correlation between physicochemical properties of SINPs and potency,  $\beta$ , based on mitochondrial protein responses (correlation coefficient –  $r$  ( $p$  value))

| Physical/chemical properties                                 |                    |                        |                         |                |                |               |                       |                |                |                                 |                       |
|--|--------------------|------------------------|-------------------------|----------------|----------------|---------------|-----------------------|----------------|----------------|---------------------------------|-----------------------|
| Protein name   | Total metals (ppm) | Bioactive metals (ppm) | Transition metals (ppm) | DLS size (nm)  | TEM size (nm)  | DLS/TEM ratio | TGA functional groups | DLS size (nm)  | DLS/TEM ratio  | TEM SA $\times$ (DLS/TEM ratio) | TGA functional groups |
| Dihydropyridyl dehydrogenase, mitochondrial                  |                    |                        |                         |                |                |               | -0.977 (0.023)        |                |                |                                 | -0.971 (0.006)        |
| Aspartate aminotransferase, mitochondrial                    |                    |                        |                         |                | -0.975 (0.025) |               | -0.96 (0.040)         |                | -0.883 (0.047) | -0.894 (0.041)                  | -0.949 (0.014)        |
| Malate dehydrogenase, mitochondrial                          | 1 (0.018)          | 0.999 (0.025)          | 0.997 (0.046)           |                |                |               |                       |                |                | -0.863 (0.059)                  | -0.909 (0.032)        |
| Superoxide dismutase [Mn], mitochondrial                     |                    |                        |                         |                |                |               |                       |                |                |                                 |                       |
| Cytochrome c oxidase subunit 5B, mitochondrial               | 0.995 (0.064)      |                        |                         |                | -0.936 (0.064) |               | -0.954 (0.046)        |                | -0.896 (0.040) | -0.917 (0.029)                  | -0.953 (0.012)        |
| Glutamate dehydrogenase 1, mitochondrial                     | 0.999 (0.028)      | 0.999 (0.020)          | 1 (0.001)               |                |                |               | -0.954 (0.046)        |                | -0.892 (0.042) | -0.892 (0.042)                  | -0.951 (0.013)        |
| Ornithine aminotransferase, mitochondrial                    |                    |                        |                         |                |                |               |                       | -0.751 (0.052) | -0.964 (0.008) | -0.946 (0.015)                  |                       |
| Cytochrome c, somatic  |                    |                        |                         | -0.752 (0.051) |                |               |                       |                |                |                                 |                       |
| ATP synthase subunit alpha, mitochondrial                    |                    |                        |                         |                |                |               |                       |                | -0.875 (0.052) | -0.896 (0.040)                  | -0.953 (0.012)        |
| Ubiquinone biosynthesis protein COQ9, mitochondrial          |                    |                        |                         | -0.736 (0.059) |                |               |                       |                |                |                                 |                       |
| Aconitate hydratase, mitochondrial                           | 0.997 (0.047)      | 0.996 (0.055)          |                         |                |                |               | -0.953 (0.047)        |                | -0.879 (0.049) | -0.895 (0.040)                  | -0.946 (0.015)        |
| Heat shock protein 75 kDa, mitochondrial                     |                    |                        |                         |                |                |               | -0.969 (0.031)        |                | -0.899 (0.038) | -0.903 (0.036)                  | -0.95 (0.013)         |
| Acyl carrier protein, mitochondrial                          |                    |                        |                         |                | -0.979 (0.021) |               |                       |                |                |                                 |                       |
| ATP synthase subunit delta, mitochondrial                    | -1 (0.006)         | -1 (0.002)             | 0.999 (0.023)           |                |                |               |                       |                |                |                                 |                       |
| Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  |                    |                        |                         |                |                |               |                       |                |                |                                 |                       |
| Electron transfer flavoprotein subunit beta {ECO:0000305}    |                    |                        |                         |                | -0.954 (0.046) |               |                       |                | -0.865 (0.058) | -0.892 (0.042)                  | -0.941 (0.017)        |
| Isocitrate dehydrogenase [NADP], mitochondrial               |                    |                        | 0.997 (0.052)           |                |                |               |                       |                | -0.89 (0.043)  | -0.911 (0.031)                  | -0.911 (0.032)        |
| NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial | 1 (0.011)          | 1 (0.004)              | 1 (0.018)               |                |                |               |                       |                |                | -0.858 (0.063)                  | -0.924 (0.025)        |
| NFU1 iron-sulfur cluster scaffold homolog, mitochondrial     | 0.999 (0.034)      | 0.999 (0.027)          | 1 (0.005)               |                |                |               |                       |                |                | -0.891 (0.042)                  | -0.905 (0.035)        |
| Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  |                    |                        |                         |                |                |               |                       |                |                |                                 |                       |
| Cytochrome c oxidase subunit NDUF4A                          | 1 (0.003)          | 1 (0.010)              | 0.999 (0.032)           |                |                |               |                       |                |                |                                 |                       |
| Stress-70 protein, mitochondrial                             |                    |                        |                         |                |                |               |                       |                |                |                                 |                       |
| ATP synthase subunit beta, mitochondrial                     |                    |                        |                         |                |                |               |                       |                | -0.86 (0.06)   | -0.894 (0.041)                  | -0.857 (0.064)        |
|  |                    |                        |                         |                |                |               |                       |                |                |                                 | -0.874 (0.053)        |

## Physical/chemical properties

| Protein name  | Total metals (ppm) | Bioactive metals (ppm) | Transition metals (ppm) | DLS size (nm) | TEM size (nm) | DLS/TEM ratio | TGA functional groups | DLS/TEM ratio     | TEM SA × (DLS/TEM ratio)              | TGA functional groups |                   |
|---|--------------------|------------------------|-------------------------|---------------|---------------|---------------|-----------------------|-------------------|---------------------------------------|-----------------------|-------------------|
| Electron transfer flavoprotein subunit alpha, mitochondrial Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial |                    |                        |                         |               |               |               |                       | -0.889<br>(0.044) | -0.935<br>(0.02)<br>-0.874<br>(0.053) |                       | -0.904<br>(0.035) |


Uncoloured region in the table consists of data for all SiNPs, while data in the grey region are only for the analysis of pristine and surface-modified 15 nm SiNPs.

amorphous SiNP exposure (12–15 nm) in various cell types of lung epithelial (A549) and human and murine monocyte/macrophage cells (THP-1 and J774 cells) have also shown adverse effects on cellular ATP production.<sup>24</sup> Furthermore, nanoparticle exposures are known to initiate apoptosis by regulating proteins in the mitochondria-mediated apoptosis pathway.<sup>42</sup> Thus, based on our TEM findings in this work and all other reports mentioned above, exploring SiNP nanoform toxicity screening based on a direct exposure of mitochondrial fractions followed by proteomic analysis can provide insights in terms of mitochondrial toxicity and related mechanistic pathways. Isolated mitochondria are known to maintain many functional characteristics when in *in situ* or *in vivo* environments. There are reports on the use of isolated mitochondrial fractions for chemical toxicity testing studies.<sup>43,44</sup> In this work, mitochondrial fractions were exposed directly to SiNP nanoforms to test the applicability of this methodology to screen nanoparticles for *in vitro* mitochondrial toxicity by acquiring high-content protein-level information to see the feasibility of this method to support the efforts on a new approach methodology (NAM) in the toxicity testing of nanoforms of chemicals. Besides, the doses used for the direct exposure of mitochondrial fractions in this study were kept low to avoid observing proteomic changes related to frank toxicity. Typically, *in vitro* cytotoxicity studies have exposed cells (*e.g.* J774) to SiNPs at doses ranging from 0–2000  $\mu\text{g mL}^{-1}$ .<sup>45</sup> In our study, J774 cells were exposed to 0–100  $\mu\text{g cm}^{-2}$  in 96-well plates for cytotoxicity testing (far less compared with other reports, and the highest dose, 100  $\mu\text{g cm}^{-2}$ , is equivalent to 150  $\mu\text{g mL}^{-1}$ , based on a surface area of 0.3  $\text{cm}^2$  for a 96-well plate, and a 200  $\mu\text{L}$  total volume). The maximum dose (15  $\mu\text{g mL}^{-1}$ ) used for the exposure of the mitochondrial fraction in this work was a tenth of the highest dose used for the exposure of cells in our study.

Initial MALDI-TOF-TOF-MS profiling in this work demonstrated SiNP exposure-specific changes, in particular size- and surface-modification-specific changes in protein profiles. Furthermore, the protein mass spectral profile comparisons showed differences related to the 12 nm (commercially obtained reference particle) and 15 nm amorphous SiNP (custom synthesized) exposures even though these nanoparticles are of similar sizes, suggesting source-related differences in protein responses. Based on our previous work,<sup>24</sup> this 12 nm SiNP (+ve control) displayed high cytotoxic and inflammatory potency in multiple cell lines, relative to other SiNPs of comparable (15 nm) sizes and exhibited relatively high oxidative potential.<sup>23</sup>

Further high-content protein analyses carried out by the use of LC-MS/MS analysis exhibited identification of about 200 mitochondria-related proteins that exhibited changes related to SiNP exposures. These proteins included mitochondrial membrane and matrix proteins. Protein fold-changes (SiNP exposure groups normalized to the control) showed SiNP variant- and exposure dose-specific changes (Fig. 4), as with the initial protein profiling results. The heatmap and hierarchical clustering data also illustrate an up- and down-regulation





**Fig. 5** Pathway analysis (IPA) results based on mitochondrial protein fold-changes (normalized to controls, fold-change cut off 1.5) as associated with the different SiNP exposures.

of protein responses specific to these exposures. Some of the proteins identified are products of mitochondrial DNA (*e.g.* NADPH oxidase, ATP synthase), whereas the others are known to be synthesized by the nuclear DNA and translocated from the cytoplasm to the mitochondria (*e.g.* superoxide dismutase, aconitase). In general, exposure to the highest dose (15  $\mu\text{g mL}^{-1}$ ) of SiNPs exhibited decreased protein expressions for the smaller sized SiNPs (15 and 30 nm). However, the larger-sized SiNP variant (75 nm) showed an opposite trend where at the high dose (15  $\mu\text{g mL}^{-1}$ ) some protein responses were increased, as opposed to the low-dose exposure (5  $\mu\text{g mL}^{-1}$ ). This behaviour may be attributed to in-solution aggregation/

agglomeration of these nanoparticles at the higher dose. Similarly, with the reference particles, the more cytotoxic SiNP 12 nm (+ve control) behaved like the other SiNP variants, whereas the micron-sized  $\text{TiO}_2$  particles (–ve control) displayed changes in relatively few protein responses, at the highest dose of exposure (Fig. 4), consistent with cytotoxicity responses (data not shown). The reference control particles were incorporated into this work to mainly ensure that the cytotoxicity assay performed as expected.

The association between SiNP potency values ( $\beta$ ) derived from these protein responses at the different exposure doses and SiNP physicochemical properties (Table 3) suggests that








Fig. 5 (Contd).

the metal contents, size, surface area and surface modifications of these nanoforms can influence the toxic potencies of these nanoparticles. Interestingly, a positive correlation was seen between the SiNP metal content, especially transition metals that can redox-cycle and the identified mitochondrial proteins that participate in electron transfer reactions. Meanwhile, the negative correlation between the surface modification and the associated proteins (Table 3) could perhaps be attributed to protein corona formation. Protein coronas are linked to a reduced toxicity of NPs, for instance for nano TiO<sub>2</sub> in some reports,<sup>46</sup> while they are associated with increased uptake and bioavailability and related protein-level changes.<sup>47</sup> Meanwhile, reduced agglomeration in solution as seen with relatively larger pristine SiNPs (75 nm) and with surface-modified NPs (Table 1) may also be attributed to these protein changes. Similarly, cellular ATP levels and mitochondrial ATP synthases were affected by the size, surface area and surface modification properties of these SiNPs. A SiNP exposure-led decline in ATPase activities was reported in HUVEC cells.<sup>8</sup> Size- and surface-modifications are known to influence the agglomeration behaviour of nanoparticles, and are implicated in NP-cell interactions in terms of the type of receptor-mediated cellular uptake, for instance, by endocytosis mechanisms.<sup>48,49</sup>

Pathway analyses based on protein fold-changes in the SiNP-exposed mitochondria exhibited perturbations in critical pathways such as oxidative phosphorylation, the TCA cycle II, fatty acid  $\beta$  oxidation, valine degradation and isoleucine degradation (Fig. 5A). Dose-related effects are noticed with mitochondrial proteins after SiNP exposure, and especially with some SiNP forms (including -C3COOH surface-modified SiNPs) this dose-related effect is more evident (Fig. 4, 5A and Table S1†). For instance, at lower doses some mitochondrial protein expressions were increased, whereas at higher doses a decreased expression of these proteins was noted, and similar observations are seen with mitochondrial pathways, for instance, with the oxidative phosphorylation pathway and TCA cycle (Fig. 5A). Some changes in the expression of mitochondrial proteins constituting the oxidative phosphorylation pathway (Table S1†), the main ATP-generating pathway, are, for instance, seen in complex 1-NDUFA4 and cytochrome c, after SiNP exposures. There are reports on macrophage exposure to nanoparticles (*e.g.* nano TiO<sub>2</sub>) and mitochondrial dysfunction associated with increased mitochondrial oxidative stress and reduced metabolic flux in the TCA cycle.<sup>7,50-52</sup> Besides, valine and isoleucine are branched chain amino acids and their catabolism takes place mainly in the mitochondria<sup>53</sup> and supports ATP production. It is interesting to note that these pathways



are downregulated by SiNP exposures, especially at high doses (Fig. 5A). This is consistent with our finding of decreased J774 cellular ATP levels with increasing doses of SiNPs in this study. Moreover, cellular ATP level showed a main size ( $p < 0.05$ ) effect (data not shown) consistent with mitochondrial protein changes, with especially the smaller size being more potent, as noted previously. In line with our findings, size-related cytotoxicity *in vitro* is reported in various cells including lung epithelial, monocyte macrophage, and liver and intestinal cells, and smaller sized SiNPs were shown to be relatively more cytotoxic than larger sized ones.<sup>54</sup> Yet, there were some deviations reported as well,<sup>54</sup> and these deviations were attributed to SiNP synthesis, aggregation, experimental conditions such as serum-containing medium and protein corona formation.

Furthermore, detailed analyses of these different biological events revealed particle-specific increased or decreased protein expressions within the TCA cycle, the oxidative phosphorylation system and the fatty acid oxidation pathways. For instance, in terms of fatty acid  $\beta$  oxidation, the low-dose exposure to 15 nm pristine SiNP led to increased long chain fatty acid CoA ligase, enoyl CoA hydratase,  $\beta$ -hydroxyacyl CoA dehydrogenase and acetyl CoA C-acyl transferase and no change in oxidoreductase, whereas the high-dose exposure to this SiNP variant led to a decrease in all these enzymes that are components of fatty acid  $\beta$  oxidation. Similarly, high-dose exposure to the 30 nm pristine SiNPs led to a reduction in all these enzymes, whereas when exposed to the high dose of 75 nm pristine SiNP, all enzymes were reduced except for the long chain fatty acid CoA ligase, which was unchanged.

Pathway analysis also identified that amorphous SiNP exposures adversely affected elements related to mitochondrial function such as the quantity of carnitine, concentration of fatty acid, accumulation of lipid and metabolism of reactive oxygen species (Fig. 5B). For instance, a quantity of carnitine is essential for fatty acid oxidation in the mitochondria. Deviation from normalcy can imply a potential impact on mitochondrial function as a result of exposure to these SiNPs. Our findings are consistent with previous reports.<sup>55</sup> Oxidative stress is known to affect mitochondrial functioning. An impairment in mitochondrial membrane potential, the electron transport chain, and activation of NADPH-like enzyme systems can occur as a consequence of oxidative stress.<sup>51</sup> Moreover, mitochondrial dysfunction is reported to initiate apoptosis by regulating proteins such as cytochrome c (Cyt c) and apoptosis inducing factor (AIF) which is released from the mitochondrial intermembrane space.<sup>56</sup> Interestingly, both Cyt c and AIF were perturbed by exposure to SiNPs in this work (Table S1†). The mechanistic information obtained from this work and the information on the association between the relative potencies of these nanomaterials and their physicochemical properties can be useful for the construction of quantitative structure–activity (QSAR) and adverse outcome pathway (AOP) models used for health risk analysis associated with nanomaterial exposures.

Furthermore, pathway analysis revealed that SiNP nanof orm type and exposure dose can potentially influence upstream reg-

ulators, namely CLPP, PPARGC1A, MAP4K4 and PTEN, differently (Fig. 5C). CLPP is an endopeptidase in the mitochondrial matrix and is important in maintaining mitochondrial protein homeostasis.<sup>57</sup> Also, SiNP exposures, especially at high doses, exhibited decreased PPARGC1A that coincided with decreased oxidative phosphorylation (Fig. 5A) and decreased superoxide dismutase (SOD2) (Table S1†). PPARGC1A is known to be a transcriptional co-activator and master regulator of mitochondrial function, and interestingly, a decreased level of this regulator molecule was reported to coincide with a reduced expression of oxidative phosphorylation subunits and a reduced expression of various mitochondrial antioxidants in neurodegenerative processes.<sup>58</sup> Similarly, SiNP exposures were also associated with upstream MAP4K4 and PTEN effects by this pathway analysis, and these are known to be associated with the regulation of mitochondrial function. Although the upstream regulators are based on a proteomic analysis of the mitochondrial fractions exposed to the SiNPs, not whole cells, the results obtained are still consistent with previous reports on SiNP exposure-related mitochondrial dysfunction in endothelial (HUVEC) cells.<sup>9</sup> Also, the findings from this study are consistent with the report from Lee *et al.* (2021) on mitochondrial effects after the exposure of HepG2 cells to a single nanosilica material and following proteomics changes.<sup>59</sup> Besides, mitochondrial exposure involves a relatively shorter exposure time and less material for exposure, compared with exposure of cells to these SiNPs. To our knowledge, very limited work on the application of proteomics for this purpose has thus far been done on these nanomaterials, and none on the toxicity testing of nanof orms.

Recently, to keep pace with the number of engineered nanoparticles that are entering commerce, while reducing the use of animal testing, as with chemical testing, the integration of new approach methodologies (NAMs) based on *in vitro* cellular and cell-free assays have been explored. The application of new approach methodologies is gaining importance for toxicity screening and in obtaining molecular-level information to advance the risk assessment of ENMs like amorphous SiNPs. These processes are relatively advanced for environmental chemical risk assessment efforts<sup>60,61</sup> compared with those for emerging ENM toxicity testing. This new SiNP toxicity screening study is promising as an NAM for nanomaterial toxicity testing to support risk assessment based on adverse mitochondrial effects, which come across as a key event in many adverse health outcomes.

## Conclusions

Our findings on the application of mitochondrial fractions for SiNP toxicity screening demonstrate the feasibility of using this strategy for mitochondrial perturbation-based toxicity testing and for the identification of physicochemical determinants of toxicity. Also, proteomic analysis provides insight into toxicity pathways specific to SiNP exposure-led adverse mitochondrial effects consistent with associated cellular cyto-



toxicity endpoint (ATP) and mitochondrial structural (TEM) changes. These results warrant further research on the application of high-content proteomic analysis in screening for nanomaterial toxicity testing.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The panel of the amorphous SiNPs was synthesized by Applied Quantum Materials Inc. in Edmonton, AB, Canada. We would like to pay tribute to Dr Renaud Vincent who had contributed to the inception and conduct of this work as well as to the preparation of this manuscript, and our irreparable recent loss of him while we were finalizing the manuscript is deeply felt by all of us. We are grateful to Dr Linda Johnston from NRC Canada for providing information on DLS, functional group analysis and surface area for these particles and Dr Nimal DeSilva at the Department of Earth and Environmental Sciences, University of Ottawa for conducting the ICP-MS/AES analysis. We thank Johanne Ouellette at the Facility for Electron Microscopy Research (FEMR), Department of Pharmacology and Therapeutics, McGill University for electron microscopy assistance. This work was funded by the Chemicals Management Plan (CMP) and the Nanotechnology Section, New Substances Assessment and Control Bureau (NSACB) of Health Canada (CRA).

## References

- 1 Y. X. Yang, Z. M. Song, B. Cheng, K. Xiang, X. X. Chen, J. H. Liu, A. Cao, Y. Wang, Y. Liu and H. Wang, Evaluation of the toxicity of food additive silica nanoparticles on gastrointestinal cells, *J. Appl. Toxicol.*, 2014, **34**(4), 424–435, DOI: [10.1002/jat.2962](https://doi.org/10.1002/jat.2962).
- 2 S. Sripanyakorn, R. Jugdaohsingh, W. Dissayabutr, S. H. Anderson, R. P. Thompson and J. J. Powell, The comparative absorption of silicon from different foods and food supplements, *Br. J. Nutr.*, 2009, **102**(6), 825–834, DOI: [10.1017/S0007114509311757](https://doi.org/10.1017/S0007114509311757).
- 3 M. E. Vance, T. Kuiken, E. P. Vejerano, S. P. McGinnis, M. F. Hochella, D. Rejeski Jr. and M. S. Hull, Nanotechnology in the real world: Redeveloping the nanomaterial consumer products inventory, *Beilstein J. Nanotechnol.*, 2015, **6**, 1769–1780, DOI: [10.3762/bjnano.6.181](https://doi.org/10.3762/bjnano.6.181).
- 4 Y. Wang, A. Kalinina, T. Sun and B. Nowack, Probabilistic modeling of the flows and environmental risks of nanosilica, *Sci. Total Environ.*, 2016, **545–546**, 67–76.
- 5 P. Kumarathan, E. Blais, A. Saravanamuthu, A. Bielecki, B. Mukherjee, S. Bjarnason, J. Gu nette, P. Goegan and R. Vincent, Nitrate stress, oxidative stress and plasma endothelin levels after inhalation of particulate matter and ozone, *Part. Fibre Toxicol.*, 2015, **12**, 28, DOI: [10.1186/s12989-015-0103-7](https://doi.org/10.1186/s12989-015-0103-7).
- 6 G. Oberd rster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling, D. Lai, S. Olin, N. Monteiro-Riviere, D. Warheit, H. Yang and ILSI Research Foundation/Risk Science Institute Nanomaterial Toxicity Screening Working Group, Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy, *Part. Fibre Toxicol.*, 2005, **2**, 8, DOI: [10.1186/1743-8977-2-8](https://doi.org/10.1186/1743-8977-2-8).
- 7 Q. Chen, N. Wang, M. Zhu, J. Lu, H. Zhong, X. Xue, S. Guo, M. Li, X. Wei, Y. Tao and H. Yin, TiO<sub>2</sub> nanoparticles cause mitochondrial dysfunction, activate inflammatory responses, and attenuate phagocytosis in macrophages: A proteomic and metabolomic insight, *Redox Biol.*, 2018, **15**, 266–276, DOI: [10.1016/j.redox.2017.12.011](https://doi.org/10.1016/j.redox.2017.12.011).
- 8 C. Guo, R. Ma, X. Liu, Y. Xia, P. Niu, J. Ma, X. Zhou, Y. Li and Z. Sun, Silica nanoparticles induced endothelial apoptosis via endoplasmic reticulum stress-mitochondrial apoptotic signaling pathway, *Chemosphere*, 2018, **210**, 183–192, DOI: [10.1016/j.chemosphere.2018.06.170](https://doi.org/10.1016/j.chemosphere.2018.06.170).
- 9 C. Guo, J. Wang, L. Jing, R. Ma, X. Liu, L. Gao, L. Cao, J. Duan, X. Zhou, Y. Li and Z. Sun, Mitochondrial dysfunction, perturbations of mitochondrial dynamics and biogenesis involved in endothelial injury induced by silica nanoparticles, *Environ. Pollut.*, 2018, **236**, 926–936.
- 10 L. Chen, J. Liu, Y. Zhang, G. Zhang, Y. Kang, A. Chen, X. Feng and L. Shao, The toxicity of silica nanoparticles to the immune system, *Nanomedicine*, 2018, **13**(15), 1939–1962, DOI: [10.2217/nnm-2018-0076](https://doi.org/10.2217/nnm-2018-0076).
- 11 D. Napierska, L. C. Thomassen, D. Lison, J. A. Martens and P. H. Hoet, The nanosilica hazard: another variable entity, *Part. Fibre Toxicol.*, 2010, **7**(1), 39, DOI: [10.1186/1743-8977-7-39](https://doi.org/10.1186/1743-8977-7-39).
- 12 J. Y. Kim, J. H. Park, M. Kim, H. Jeong, J. Hong, R. S. Chuck and C. Y. Park, Safety of Nonporous Silica Nanoparticles in Human Corneal Endothelial Cells, *Sci. Rep.*, 2017, **7**(1), 14566, DOI: [10.1038/s41598-017-15247-2](https://doi.org/10.1038/s41598-017-15247-2).
- 13 S. Murugadoss, D. Lison, L. Godderis, S. Van Den Brule, J. Mast, F. Brassinne, N. Sebaihi and P. H. Hoet, Toxicology of silica nanoparticles: an update, *Arch. Toxicol.*, 2017, **91**(9), 2967–3010.
- 14 Z. Du, S. Chen, G. Cui, Y. Yang, E. Zhang, Q. Wang, M. F. Lavin, A. J. Yeo, C. Bo, Y. Zhang, C. Li, X. Liu, X. Yang, C. Peng and H. Shao, Silica nanoparticles induce cardiomyocyte apoptosis via the mitochondrial pathway in rats following intratracheal instillation, *Int. J. Mol. Med.*, 2019, **43**(3), 1229–1240.
- 15 K. Lee, J. Lee, M. Kwak, Y. L. Cho, B. Hwang, M. J. Cho, N. G. Lee, J. Park, S. H. Lee, J. G. Park, Y. G. Kim, J. S. Kim, T. S. Han, H. S. Cho, Y. J. Park, S. J. Lee, H. G. Lee, W. K. Kim, I. C. Jeung, N. W. Song, K. H. Bae and J. K. Min, Two distinct cellular pathways leading to endothelial cell



- cytotoxicity by silica nanoparticle size, *J. Nanobiotechnol.*, 2019, **17**(1), 24, DOI: [10.1186/s12951-019-0456-4](https://doi.org/10.1186/s12951-019-0456-4).
- 16 F. Wang, F. Gao, M. Lan, H. Yuan, Y. Huang and J. Liu, Oxidative stress contributes to silica nanoparticle-induced cytotoxicity in human embryonic kidney cells, *Toxicol. in Vitro*, 2009, **23**(5), 808–815, DOI: [10.1016/j.tiv.2009.04.009](https://doi.org/10.1016/j.tiv.2009.04.009).
- 17 E. J. Park and K. Park, Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro, *Toxicol. Lett.*, 2009, **184**(1), 18–25, DOI: [10.1016/j.toxlet.2008.10.012](https://doi.org/10.1016/j.toxlet.2008.10.012).
- 18 Y. Ye, J. Liu, M. Chen, L. Sun and M. Lan, In vitro toxicity of silica nanoparticles in myocardial cells, *Environ. Toxicol. Pharmacol.*, 2010, **29**(2), 131–137, DOI: [10.1016/j.etap.2009.12.002](https://doi.org/10.1016/j.etap.2009.12.002).
- 19 C. Guo, Y. Xia, P. Niu, L. Jiang, J. Duan, Y. Yu, X. Zhou, Y. Li and Z. Sun, Silica nanoparticles induce oxidative stress, inflammation, and endothelial dysfunction in vitro via activation of the MAPK/Nrf2 pathway and nuclear factor- $\kappa$ B signaling, *Int. J. Nanomed.*, 2015, **10**, 1463–1477, DOI: [10.2147/IJN.S76114](https://doi.org/10.2147/IJN.S76114).
- 20 C. C. Chou, W. Chen, Y. Hung and C. Y. Mou, Molecular Elucidation of Biological Response to Mesoporous Silica Nanoparticles in Vitro and in Vivo, *ACS Appl. Mater. Interfaces*, 2017, **9**(27), 22235–22251, DOI: [10.1021/acsmi.7b05359](https://doi.org/10.1021/acsmi.7b05359).
- 21 M. Kusaczuk, R. Krętownski, M. Naumowicz, A. Stypułkowska and M. Cechowska-Pasko, Silica nanoparticle-induced oxidative stress and mitochondrial damage is followed by activation of intrinsic apoptosis pathway in glioblastoma cells, *Int. J. Nanomed.*, 2018, **13**, 2279–2294, DOI: [10.2147/IJN.S158393](https://doi.org/10.2147/IJN.S158393).
- 22 Y. Li, J. Duan, X. Chai, M. Yang, J. Wang, R. Chen and Z. Sun, Microarray-assisted size-effect study of amorphous silica nanoparticles on human bronchial epithelial cells, *Nanoscale*, 2019, **11**(47), 22907–22923.
- 23 D. Breznan, N. Nazemof, F. Kunc, M. Hill, D. Vladislavljevic, J. Gomes, L. J. Johnston, R. Vincent and P. Kumarathasan, Acellular oxidative potential assay for screening of amorphous silica nanoparticles, *Analyst*, 2020, **145**(14), 4867–4879, DOI: [10.1039/d0an00380h](https://doi.org/10.1039/d0an00380h).
- 24 D. Breznan, D. D. Das, J. S. O'Brien, C. MacKinnon-Roy, S. Nimesh, N. Q. Vuong, S. Bernatchez, N. DeSilva, M. Hill, P. Kumarathasan and R. Vincent, Differential cytotoxic and inflammatory potency of amorphous silicon dioxide nanoparticles of similar size in multiple cell lines, *Nanotoxicology*, 2017, **11**(2), 223–235, DOI: [10.1080/17435390.2017.1287313](https://doi.org/10.1080/17435390.2017.1287313).
- 25 P. Kumarathasan, D. Das, M. A. Salam, S. Mohattalage, N. DeSilva, B. Simard and R. Vincent, Mass spectrometry-based proteomic assessment of the in vitro toxicity of carbon nanotubes, *Curr. Top. Biochem. Res.*, 2012, **14**, 15–27.
- 26 M. B. Ariganello, D. Das, D. Breznan, C. MacKinnon-Roy, F. Elisma, A. Khanchi, R. Vincent and P. Kumarathasan, A MALDI-TOF-TOF-MS-based Toxicoproteomic Screening Method to Assess In Vitro Particle Potencies, *J. Appl. Toxicol.*, 2018, **38**(10), 1302–1315, DOI: [10.1002/jat.3642](https://doi.org/10.1002/jat.3642), Epub 2018 May 29.
- 27 P. Kumarathasan, S. Mohottalage, P. Goegan and R. Vincent, An optimized protein in-gel digest method for reliable proteome characterization by MALDI-TOF-MS analysis, *Anal. Biochem.*, 2005, **346**(1), 85–89, DOI: [10.1016/j.ab.2005.06.004](https://doi.org/10.1016/j.ab.2005.06.004).
- 28 R. Vincent, P. Goegan, G. Johnson, J. R. Brook, P. Kumarathasan, L. Bouthillier and R. T. Burnett, Regulation of promoter-CAT stress genes in HepG2 cells by suspensions of particles from ambient air, *Fundam. Appl. Toxicol.*, 1997, **39**(1), 18–32, DOI: [10.1006/faat.1997.2336](https://doi.org/10.1006/faat.1997.2336).
- 29 S. J. So, I. S. Jang and C. S. Han, Effect of micro/nano silica particle feeding in mice, *J. Nanosci. Nanotechnol.*, 2008, **8**(10), 5367–5371.
- 30 Y. Yang, J. J. Faust, J. Schoepf, K. Hristovski, D. G. Capco, P. Herckes and P. Westerhoff, Survey of food-grade silica dioxide nanomaterial occurrence, characterization, human gut impacts and fate across its lifecycle, *Sci. Total Environ.*, 2016, **565**, 902–912.
- 31 C. Guo, J. Wang, M. Yang, Y. Li, S. Cui, X. Zhou, Y. Li and Z. Sun, Amorphous silica nanoparticles induce malignant transformation and tumorigenesis of human lung epithelial cells via P53 signaling, *Nanotoxicology*, 2017, **11**(9–10), 1176–1194.
- 32 A. M. Walters, G. A. Porter Jr. and P. S. Brookes, Mitochondria as a drug target in ischemic heart disease and cardiomyopathy, *Circ. Res.*, 2012, **111**(9), 1222–1236, DOI: [10.1161/CIRCRESAHA.112.265660](https://doi.org/10.1161/CIRCRESAHA.112.265660).
- 33 A. Salminen, J. Ojala, K. Kaarniranta and A. Kauppinen, Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases, *Cell. Mol. Life Sci.*, 2012, **69**(18), 2999–3013, DOI: [10.1007/s00018-012-0962-0](https://doi.org/10.1007/s00018-012-0962-0).
- 34 E. Desideri, R. Vegliante and M. R. Ciriolo, Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity, *Cancer Lett.*, 2015, **356**(2 Pt A), 217–223, DOI: [10.1016/j.canlet.2014.02.023](https://doi.org/10.1016/j.canlet.2014.02.023).
- 35 S. Cardaci and M. R. Ciriolo, TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State, *Int. J. Cell Biol.*, 2012, 161837, DOI: [10.1155/2012/161837](https://doi.org/10.1155/2012/161837).
- 36 J. Nunnari and A. Suomalainen, Mitochondria: in sickness and in health, *Cell*, 2012, **148**(6), 1145–1159, DOI: [10.1016/j.cell.2012.02.035](https://doi.org/10.1016/j.cell.2012.02.035).
- 37 G. Zsurka and W. S. Kunz, Mitochondrial involvement in neurodegenerative diseases, *IUBMB Life*, 2013, **65**(3), 263–272, DOI: [10.1002/iub.1126](https://doi.org/10.1002/iub.1126).
- 38 C. E. Nichols, D. L. Shepherd, Q. A. Hathaway, A. J. Durr, D. Thapa, A. Abukabda, J. Yi, T. R. Nurkiewicz and J. M. Hollander, Reactive oxygen species damage drives cardiac and mitochondrial dysfunction following acute nano-titanium dioxide inhalation exposure, *Nanotoxicology*, 2018, **12**(1), 32–48.
- 39 K. C. Nguyen, Y. Zhang, J. Todd, K. Kittle, M. Lalande, S. Smith, D. Parks, M. Navarro, A. F. Tayabali and W. G. Willmore, Hepatotoxicity of Cadmium Telluride





- Quantum Dots Induced by Mitochondrial Dysfunction, *Chem. Res. Toxicol.*, 2020, 33(9), 2286–2297, DOI: [10.1021/acs.chemrestox.9b00526](https://doi.org/10.1021/acs.chemrestox.9b00526).
- 40 J. Skalska, B. Dąbrowska-Bouta, M. Frontczak-Baniewicz, G. Sulkowski and L. Strużyńska, A Low Dose of Nanoparticulate Silver Induces Mitochondrial Dysfunction and Autophagy in Adult Rat Brain, *Neurotox. Res.*, 2020, 38(3), 650–664, DOI: [10.1007/s12640-020-00239-4](https://doi.org/10.1007/s12640-020-00239-4).
- 41 M. Enea, E. Pereira, M. P. de Almeida, A. M. Araújo, M. de Lourdes Bastos and H. Carmo, Gold Nanoparticles Induce Oxidative Stress and Apoptosis in Human Kidney Cells, *Nanomaterials*, 2020, 10(5), 995.
- 42 M. A. Siddiqui, H. A. Alhadlaq, J. Ahmad, A. A. Al-Khedhairi, J. Musarrat and M. Ahamed, Copper oxide nanoparticles induced mitochondria mediated apoptosis in human hepatocarcinoma cells, *PLoS One*, 2013, 8(8), e69534, DOI: [10.1371/journal.pone.0069534](https://doi.org/10.1371/journal.pone.0069534).
- 43 C. V. Pereira, A. C. Moreira, S. P. Pereira, N. G. Machado, F. S. Carvalho, V. A. Sardão and P. J. Oliveira, Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety?, *Curr. Drug Saf.*, 2009, 4(1), 34–54, DOI: [10.2174/157488609787354440](https://doi.org/10.2174/157488609787354440).
- 44 R. D. Shannon, G. D. Boardmann and A. M. Dietrich, Mitochondrial response to chlorophenols as a short-term toxicity assay, *Environ. Toxicol. Chem.*, 1991, 10, 57–66.
- 45 L. C. Thomassen, A. Aerts, V. Rabolli, D. Lison, L. Gonzalez, M. Kirsch-Volders, D. Napierska, P. H. Hoet, C. E. Kirschhock and J. A. Martens, Synthesis and characterization of stable monodisperse silica nanoparticle sols for in vitro cytotoxicity testing, *Langmuir*, 2010, 26(1), 328–335.
- 46 S. Runa, M. Lakadamyali, M. L. Kemp and C. K. Payne, TiO<sub>2</sub> Nanoparticle-Induced Oxidation of the Plasma Membrane: Importance of the Protein Corona, *J. Phys. Chem. B*, 2017, 121(37), 8619–8625.
- 47 C. F. Borgognoni, M. Mormann, Y. Qu, M. Schäfer, K. Langer, C. Öztürk, S. Wagner, C. Chen, Y. Zhao, H. Fuchs and K. Riehemann, Reaction of human macrophages on protein corona covered TiO<sub>2</sub> nanoparticles, *Nanomedicine*, 2015, 11(2), 275–282.
- 48 M. Ansar, D. Serrano, I. Papademetriou, T. K. Bhowmick and S. Muro, Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting, *ACS Nano*, 2013, 7(12), 10597–10611.
- 49 D. Breznan, D. D. Das, C. MacKinnon-Roy, S. Bernatchez, A. Sayari, M. Hill, R. Vincent and P. Kumarathan, Physicochemical Properties Can Be Key Determinants of Mesoporous Silica Nanoparticle Potency in Vitro, *ACS Nano*, 2018, 12(12), 12062–12079, DOI: [10.1021/acsnano.8b04910](https://doi.org/10.1021/acsnano.8b04910).
- 50 E. Huerta-Garcia, A. Montiel-Dayalos, M. Ramos-Godinez, E. Alfaro-Moreno and R. Lopez-Marure, Effect of titanium dioxide nanoparticles on the inflammatory process, *Mater. Sci.*, 2014, 8(3), 303–326.
- 51 A. Manke, L. Wang and Y. Rojanasakul, Mechanisms of nanoparticle-induced oxidative stress and toxicity, *BioMed Res. Int.*, 2013, 942916, DOI: [10.1155/2013/942916](https://doi.org/10.1155/2013/942916).
- 52 M. Xia, Y. Zhang, K. Jin, Z. Lu, Z. Zeng and W. Xiong, Communication between mitochondria and other organelles: a brand-new perspective on mitochondria in cancer, *Cell Biosci.*, 2019, 9, 27, DOI: [10.1186/s13578-019-0289-8](https://doi.org/10.1186/s13578-019-0289-8).
- 53 P. Schertl, L. Danne and H. P. Braun, 3-Hydroxyisobutyrate Dehydrogenase Is Involved in Both, Valine and Isoleucine Degradation in Arabidopsis thaliana, *Plant Physiol.*, 2017, 175(1), 51–61, DOI: [10.1104/pp.17.00649](https://doi.org/10.1104/pp.17.00649).
- 54 X. Dong, Z. Wu, X. Li, L. Xiao, M. Yang, Y. Li, J. Duan and Z. Sun, The Size-dependent Cytotoxicity of Amorphous Silica Nanoparticles: A Systematic Review of in vitro Studies, *Int. J. Nanomed.*, 2020, 15, 9089–9113.
- 55 L. Sun, Y. Li, X. Liu, M. Jin, L. Zhang, Z. Du, C. Guo, P. Huang and Z. Sun, Cytotoxicity and mitochondrial damage caused by silica nanoparticles, *Toxicol. in Vitro*, 2011, 25(8), 1619–1629, DOI: [10.1016/j.tiv.2011.06.012](https://doi.org/10.1016/j.tiv.2011.06.012).
- 56 C. Wang and R. J. Youle, The role of mitochondria in apoptosis\*, *Annu. Rev. Genet.*, 2009, 43, 95–118, DOI: [10.1146/annurev-genet-102108-134850](https://doi.org/10.1146/annurev-genet-102108-134850).
- 57 A. Corneo, F. Sanguedolce, V. Pesce and C. Musicco, Mitochondrial Caseinolytic protease P: A possible novel prognostic marker and therapeutic target in cancer, *Int. J. Mol. Sci.*, 2012, 22, 6228, DOI: [10.3390/ijms22126228](https://doi.org/10.3390/ijms22126228).
- 58 M. E. Witte, P. G. Nijland, J. A. R. Drexhage, W. Gerritsen, D. Geerts, B. V. H. Hof, A. Reijkerkerk, H. E. de Vries, P. V. D. Valk and J. V. Horssen, Reduced expression of PGC-1 $\alpha$  partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex, *Acta Neuropathol.*, 2013, 125, 231–243, DOI: [10.1007/s00401-012-1052-y](https://doi.org/10.1007/s00401-012-1052-y).
- 59 S. Y. Lee, I. Y. Kim, M. B. Heo, J. H. Moon, J. G. Son and T. G. Lee, Global Proteomics to Study Silica Nanoparticle-Induced Cytotoxicity and Its Mechanisms in HepG2 Cells, *Biomolecules*, 2021, 11(3), 375, DOI: [10.3390/biom11030375](https://doi.org/10.3390/biom11030375).
- 60 M. J. Aardema and J. T. MacGregor, Toxicology and genetic toxicology in the new era of “toxicogenomics”: impact of “-omics” technologies, *Mutat. Res.*, 2002, 499(1), 13–25, DOI: [10.1016/s0027-5107\(01\)00292-5](https://doi.org/10.1016/s0027-5107(01)00292-5).
- 61 K. E. Tollefsen, S. Scholz, M. T. Cronin, S. W. Edwards, J. de Knecht, K. Crofton, N. Garcia-Reyero, T. Hartung, A. Worth and G. Patlewicz, Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA), *Regul. Toxicol. Pharmacol.*, 2014, 70(3), 629–640, DOI: [10.1016/j.yrtph.2014.09.009](https://doi.org/10.1016/j.yrtph.2014.09.009).

